Cellectis (NASDAQ:CLLS) Price Target Lowered to $4.00 at Barclays

Cellectis (NASDAQ:CLLS) had its price objective reduced by Barclays from $5.00 to $4.00 in a research report sent to investors on Tuesday,Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock.

Separately, StockNews.com downgraded shares of Cellectis from a “buy” rating to a “hold” rating in a research note on Monday.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $1.41 on Tuesday. Cellectis has a twelve month low of $1.10 and a twelve month high of $3.10. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $78.37 million, a PE ratio of -1.08 and a beta of 3.11. The firm has a fifty day simple moving average of $1.37 and a 200 day simple moving average of $1.59.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $12.03 million during the quarter, compared to the consensus estimate of $12.71 million. On average, sell-side analysts forecast that Cellectis will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN grew its holdings in shares of Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 12,500 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Cellectis during the fourth quarter valued at about $962,000. Finally, B Group Inc. acquired a new position in shares of Cellectis during the fourth quarter valued at about $5,547,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.